Uptake of direct-acting antivirals for chronic hepatitis C virus infection following unrestricted access in the Netherlands

April 08, 2018

Share article

Patients with chronic hepatitis C virus (HCV) infection in the Netherlands have had unrestricted access to direct-acting antivirals (DAAs) since November 2015. The authors were interested in the uptake of these drugs among HIV/HCV-coinfected patients. They used data from an HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had one or more positive HCV RNA tests, did not spontaneously clear and were known to still be in care. Of 23,574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men [MSM], 15% people who [formerly] injected drugs and 15% via another route) were included. 87% of these 1471 patients initiated HCV treatment between 2000 and 2017, 76% of 1471 were cured and for 6% DAA treatment results were pending. Among MSM 83% (were cured and for 6% DAA treatment results were pending. 187 patients never initiated treatment, 14 patients failed on DAAs and 54 patients failed on a pegylated interferon-alpha based regimen. Therefore 15 months after the unrestricted access to DAA, the majority of HIV/HCV-coinfected patients in the Netherlands had been cured (76%) or were still awaiting DAA treatment results (6%).

Read more here

Boerekamps A, Newsum AM, Smit C, Arends JE, Richter C, et al. ISSN: Clin Infect Dis; doi: 10.1093/cid/cix1004


Added: April 08, 2018